NEW YORK TIMES BESTSELLERWashington insiders operate by a proven credo: when a Peter Schweizer book drops, duck and brace for impact. For over a decade, the work of five-time New York Times bestsell
Controlling Pharmaceutical Risks is a case study of changes in drug testing since the late 1990s, specifically geneticization of carcinogenic risk assessment and regulation of pharmaceuticals. Radical
In the first and only inside account of the Mueller investigation, one of the Special Counsel’s most trusted prosecutors breaks his silence on the team’s history-making search for the truth, their pai
